What guidance did Evotec's management provide for the next earnings period?

What is the revenue and EPS growth rate for Evotec year over year?

What is the market's earnings forecast for Evotec next quarter?

What is Evotec's gross profit margin?

What were the key takeaways from Evotec's earnings call?

What does Evotec do and what are its main business segments?

What factors drove the changes in Evotec's revenue and profit?

Did Evotec beat or miss consensus estimates last quarter?

- **Landmark Sandoz Deal**: EUR 350 million upfront + EUR 650 million+ future payments for JEB's continuous manufacturing tech, shifting to high-margin licensing.
- **Cost Efficiency**: EUR 60 million+ cost cuts in 2025, with 33% R&D spending reduction to EUR 27.7 million.
- **Pipeline Momentum**: 4 Phase II assets in 2026, EUR 16 billion+ milestone potential, and 100+ partnered projects.
- **AI/Science Leadership**: 90%+ predictive accuracy in safety tox, expanded molecular database, and J.POD licensing to Sandoz.
- **Mixed Market**: JEB non-Sandoz growth 105%, but D&P&D faces softness with cautious biotech spending.

**【CEO Summary Section】**
- Group revenues for the first 9 months of 2025 were EUR 535.1 million, a 7% decline year-over-year, driven by a 12% decline in D&P&D (Drug Discovery and Preclinical Development) business. However, Just-Evotec Biologics (JEB) grew 11% to EUR 143.2 million.
- The company announced a landmark deal with Sandoz, including a EUR 350 million upfront payment and potential future revenues of over EUR 650 million from technology licensing, development, and royalties.
- Cost-cutting initiatives aim to achieve EUR 60 million in 2025 and an additional EUR 50 million in future years. Negative change orders in D&P&D normalized in Q3, with proposals up 20% over the past two quarters.
- The partnered asset pipeline now includes 4 molecules expected to enter Phase II clinical trials in 2026, with a non-risk-adjusted milestone potential of over EUR 16 billion.

**【CFO Financial Commentary】**
- Adjusted EBITDA for the first 9 months was negative EUR 16.0 million, reflecting weaker D&P&D revenues and fixed costs. Free cash flow improved 14% year-over-year despite one-time payments.
- JEB's non-Sandoz and non-DoD (Drug Optimization) business grew 105%, outpacing Sandoz's low-single-digit growth. The transaction with Sandoz is expected to strengthen liquidity post-closure.
- R&D spending decreased 33% to EUR 27.7 million, redirected to strategic partnerships. The company reaffirmed 2025 guidance of EUR 760-800 million revenue and EUR 30-50 million EBITDA.

**【CSO Scientific Update】**
- Evotec's AI-enabled platforms (e.g., E.INVENT, AE safety tools) achieved predictive accuracies of over 90% for liver and cardiotoxicity, driving partnerships and pipeline growth.
- The molecular patient database expanded into kidney, obesity, and immunological diseases, supporting strategic deals and milestone payments.
- The J.POD continuous manufacturing platform was licensed to Sandoz, with potential for further cell line and media licensing. Over 100 partnered assets, 60% in strategic collaborations, target EUR 500 million in returns by 2028.

**【Q&A Highlights】**
- **Sandoz Deal Impact**: The transaction reduces manufacturing CAPEX, shifting to high-margin licensing. 2/3 of future payments will be development-related, with 1/3 from milestones and royalties.
- **D&P&D Outlook**: While green shoots (20% increase in proposals) suggest stabilization,2026 growth remains uncertain, with cautious spending from biotech customers.
- **NAMs Adoption**: Pharma interest in early-stage NAMs is rising, but revenue acceleration is expected in 12-24 months as platforms industrialize.
- **2028 Trajectory**: Mid-term targets of 8-12% revenue CAGR and >20% EBITDA margin are achievable, with JEB leading growth and D&P&D recovery.


Evotec SE (EVO) Q3 2025 Earnings Call Transcript

- **Revenue Split**: D&amp;PD (-11%) vs. JEB (+16%), with JEB non-Sandoz/DOD up 87%.
- **Cost Efficiency**: EUR 60M+ savings, 600 FTE reduction, liquidity EUR 348M.
- **JEB Pivot**: Sandoz deal (USD 300M) transitions to asset-light model, retaining tech upside.
- **Market Trends**: Early-stage R&D cautious, China showing traction, JEB cell line/media market growth.
- **Strategic Tech**: MPD expanded to 27,000+ patients, enabling novel targets in women's health/obesity.

**【CEO Summary Section】**
- **Strategic Progress**: Confirmed on-track execution of 2025-2028 strategy, with D&amp;PD segment revenue down 11% (temporarily impacted by BMS change orders) and JEB up 16%.
- **Market Dynamics**: Early-stage R&D funding remains cautious, with higher change orders in Q1-Q2, but normalized in Q3. JEB non-Sandoz/DOD revenue grew 87%.
- **JEB Pivot**: Transitioning to asset-light model via Sandoz deal (USD 300M consideration), retaining IP and tech upside. JEB cell line/media market growth expected.
- **Technology Leadership**: Molecular patient database (MPD) expanded to 27,000+ patients, enabling novel targets in women's health and obesity.

**【CFO Financial Commentary】**
- **H1 2025 Results**: Total revenue EUR 371M (-5%), D&amp;PD EUR 269M (-11%), JEB EUR 102.2M (+16%). Adjusted EBITDA -EUR 1.9M (vs. +EUR 11.3M prior year).
- **Cost Efficiency**: EUR 60M+ cost-out (EUR 30M from Priority Reset), 600 FTE reduction (vs. target 400). Operating cash flow improved Q2, liquidity EUR 348M.
- **Sandoz Deal**: USD 300M site sale + tech license, with future development, milestone, and royalty revenue streams.

**【Q&A Key Highlights】**
- **D&amp;PD Recovery**: Softness expected to persist, with cautious spending in early-stage R&D. Transactional business more price-sensitive, strategic partnerships less so.
- **JEB Mix**: Current revenue blend of development/production and tech access, shifting to higher-margin licensing. Non-Sandoz growth driven by 3 large pharma customers.
- **Sandoz Strategy**: Monetizes asset while retaining IP and tech leverage. Deal reflects JEB's world-class continuous manufacturing tech.
- **Geographic Trends**: China showing traction, Europe/U.S. mixed. Evotec positioned to benefit from global recovery.
- **AI Integration**: Evotec's omics-driven platforms (e.g., MPD) align with FDA's computational modeling push, enhancing target validation and drug design.

Evotec SE (EVO) Q2 2025 Earnings Call Transcript

- **Revenue Mixed**: Shared R&D down 10% YoY (-€14.6 million), offset by Just Biologics +16% YoY (+€8.3 million). Q1 EBITDA €3.1 million vs. €10.2 million YoY.
- **BMS Collaboration**: €75 million payment received, with expanded molecular glue degrader pipeline driving future work packages.
- **Cost Savings Progress**: €20 million cost out plan 50% implemented, with full impact from Q2+.
- **Strategic Focus**: AI-driven platforms (E.MPD, PanOmics) positioned to benefit from FDA's shift away from animal testing.
- **2025 Outlook**: Reaffirms €30-50 million EBITDA, with H2 Shared R&D recovery contingent on BMS activity and reduced transactional work.

**【CEO Summary Section】**
- **Q1 2025 Revenue**: €200 million (-4% YoY), with Shared R&D declining 10% YoY to €140.6 million due to soft market conditions, while Just-Evotec Biologics grew 16% YoY to €59.4 million.
- **Strategic Highlights**: Expanded collaboration with BMS in molecular glue degraders, receiving €75 million in performance-based payments. Secured a Korean government grant for lung fibrosis research.
- **Technology Leadership**: Emphasized platforms like E.MPD (molecular patient database), iPSC, PanOmics, and PanHunter, generating 500 billion data points from 20,000 patients.
- **Market Outlook**: Maintains 2025 guidance of €30-50 million EBITDA, expecting Shared R&D recovery in H2 2025 driven by BMS work packages and reduced transactional work.

**【CFO Financial Commentary】**
- **Financial Performance**: Adjusted EBITDA of €3.1 million (vs. €10.2 million in Q1 2024), driven by Just Biologics' €10 million contribution. Operating cash flow improved due to BMS payments and reduced working capital.
- **Cost Optimization**: Reduced R&D spending by 33% YoY, with 50% of planned cost savings (€20 million) implemented by Q1. Full impact expected in Q2+.
- **Liquidity**: €371 million cash, net debt €107 million (5.97x EBITDA), with covenant waivers until Q3 2025.
- **Guidance**: Reaffirms 2025 targets: €840-880 million revenue, €40-50 million R&D, and €30-50 million EBITDA.

**【Q&A Key Highlights】**
- **Market Softness**: CEO attributes Shared R&D decline to cautious pharma/biotech spending, but notes Just Biologics is diversifying customer base beyond Sandoz.
- **BMS Impact**: €75 million BMS payment in Q1, with additional work packages expected to stabilize Shared R&D in H2.
- **FDA & Tariffs**: CFO highlights Evotec's AI-driven platforms (e.g., iPSC, PanOmics) as compliant with FDA's shift away from animal testing. U.S. manufacturing expansion may benefit from tariff-related demand.
- **Layoffs & CRO Demand**: CEO sees potential for increased outsourcing as pharma/biotech layoffs reduce in-house capacity, but notes market remains cautious.


Actual	0.4703		-0.2162	-0.0799	-0.1399	0.0549	-0.0433	-0.1178	-0.0656	-0.2979	-0.1181	-0.1312	-0.1021	-0.1417	-0.1377
Forecast		0.0654	0.0324	-0.0828	-0.0081	0.0879	-0.0605	-0.0287	-0.0255	-0.0382	-0.06	0.0156	-0.0454	-0.0735	-0.0769	0.1075
Surprise	0.00%	0.00%	-767.28%	+3.50%	-1627.16%	-37.54%	+28.43%	-310.45%	-157.25%	-679.84%	-96.83%	-941.03%	-124.89%	-92.79%	-79.06%	0.00%

EVO

EVO fundamentals

EVO Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

EVO

EVO fundamentals

EVO Q4 2025 Earnings Preview

Earnings Call

EVO Earnings Call Summary for Q4/2025Upcoming6:00 AM on Apr 8, 2026

EVO Earnings Call Summary for Q3/20258:00 AM on Nov 5, 2025

EVO Earnings Call Summary for Q2/20258:00 AM on Aug 13, 2025

EVO Earnings Call Summary for Q1/2025Invalid Date on May 6, 2025

EVO Earnings Call Summary for Q4/2024 Apr 1, 2026

You can ask Aime